Gilead Trodelvy First-Line TNBC Approval
The FDA approved Trodelvy for first-line metastatic triple-negative breast cancer, significantly expanding Gilead’s commercial opportunity and reinforcing TROP2-directed ADCs as a leading oncology modality.
Gilead Sciences
Gilead – $5B Tubulis Acquisition
Gilead Sciences has agreed to acquire German biotech Tubulis in a deal worth up to $5 billion, significantly expanding its antibody-drug conjugate (ADC) platform capabilities. The transaction underscores the strategic importance of ADC technologies…
